AstraZeneca will pay Dizal Jiangsu Pharmaceutical $600 million upfront for global rights to a lung cancer drug in a $1.5 billion deal.
bloomberg-industries07/14, 01:56 PM
- $1.5 Billion
- $600 million
- 90%
Figures as quoted by bloomberg-industries
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/17, 01:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.